Updated Investor Presentation - August 2023
Filed with ASX · · 26 pages · English
The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with p
Genetic Technologies Limited on 6ix
In the deck
Story so far
Earlier from Genetic Technologies
- Appendix 4C and Quarterly Activities Report - June 2023
- Publication Validates geneType for Melanoma Risk Assessment
- Appendix 4C & Quarterly Activities Report - March 2023
- Publication Validates geneType Prostate Cancer Risk Test
- GeneType MultiTest Panel Expanded Inclusion of New Diseases
Later from Genetic Technologies
- 2023 Annual Report and Appendix 4E
- Annual Results Momentum Building on our Commercial Plans
- geneType Granted Approval for 3 New Diseases in Australia
- MRFF Grant Names GTG as Sole Industry Partner
- GTG & Gold Coast Hospital Announce Precision Medicine Pilot
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies